# Esperion Therapeutics Inc. (ESPR)

**Exchange:** NASDAQ  
**Sector:** Healthcare  
**Market cap:** $653M  
**Price:** $3.14

> Esperion Therapeutics Inc. is a pharmaceutical company that develops and commercializes oral, once-daily, non-statin medicines designed for patients with elevated low-density lipoprotein cholesterol. The company's primary marketed products are NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe), which serve patients with primary hyperlipidemia, including those with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional LDL-C lowering. These therapies address patients who are statin-intolerant or require supplementary cholesterol management beyond traditional treatments. Esperion has expanded its global reach through partnerships, with its bempedoic acid products now available in markets including Japan and Canada. The company operates in the cardiovascular health segment, focusing on closing treatment gaps in dyslipidemia management. Founded in 1998 and headquartered in Ann Arbor, Michigan, Esperion operates as a commercial-stage biopharmaceutical company dedicated to advancing treatment options for patients with elevated cholesterol and related cardiovascular risk factors.

## Income Statement (Annual, USD)

| Fiscal Year | Revenue | Gross Profit | Operating Income | Net Income | EPS (dil.) |
| --- | --- | --- | --- | --- | --- |
| 2025 | $403M | — | $60M | -$23M | $-0.11 |
| 2024 | $332M | — | $54M | -$52M | $-0.28 |
| 2023 | $116M | — | -$156M | -$209M | $-2.03 |
| 2022 | $75M | — | -$180M | -$234M | $-3.52 |
| 2021 | $78M | — | -$227M | -$269M | $-9.31 |
| 2020 | $228M | — | -$121M | -$144M | $-5.23 |
| 2019 | $148M | — | -$93M | -$97M | $-3.59 |
| 2018 | — | — | -$205M | -$202M | — |

## Balance Sheet (Annual, USD)

| Fiscal Year | Total Assets | Total Liabilities | Equity | Cash | Long-term Debt |
| --- | --- | --- | --- | --- | --- |
| 2025 | $466M | $768M | -$302M | $168M | — |
| 2024 | $344M | $733M | -$389M | $145M | — |
| 2023 | $206M | $661M | -$455M | $82M | — |
| 2022 | $248M | $572M | -$324M | $125M | — |
| 2021 | $382M | $579M | -$197M | $209M | — |
| 2020 | $353M | $449M | -$96M | $305M | — |
| 2019 | $214M | $194M | $20M | $166M | — |
| 2018 | $143M | $64M | $79M | $37M | — |

## Cash Flow (Annual, USD)

| Fiscal Year | Operating Cash Flow | CapEx | Free Cash Flow |
| --- | --- | --- | --- |
| 2025 | -$13M | — | -$13M |
| 2024 | -$24M | $317,000 | -$24M |
| 2023 | -$135M | — | -$135M |
| 2022 | -$175M | — | -$175M |
| 2021 | -$264M | — | -$264M |
| 2020 | -$85M | $869,000 | -$86M |
| 2019 | -$70M | $953,000 | -$71M |
| 2018 | -$149M | $151,000 | -$149M |
| 2017 | -$131M | $19,000 | -$131M |
| 2016 | -$48M | $94,000 | -$48M |
| 2015 | -$38M | $325,000 | -$38M |

Source: [CompaniesByCap](https://companiesbycap.com/company/ESPR)